Mu‐Yang Huang

965 total citations
20 papers, 690 citations indexed

About

Mu‐Yang Huang is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Mu‐Yang Huang has authored 20 papers receiving a total of 690 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 9 papers in Immunology and 5 papers in Oncology. Recurrent topics in Mu‐Yang Huang's work include Cancer Immunotherapy and Biomarkers (5 papers), Phagocytosis and Immune Regulation (4 papers) and Cancer Mechanisms and Therapy (3 papers). Mu‐Yang Huang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Phagocytosis and Immune Regulation (4 papers) and Cancer Mechanisms and Therapy (3 papers). Mu‐Yang Huang collaborates with scholars based in Macao, China and Hungary. Mu‐Yang Huang's co-authors include Jin‐Jian Lu, Lele Zhang, Xiaoming Jiang, Xiuping Chen, Yulian Xu, Yang Sun, Binglin Wang, Jian Ding, Yu‐Chi Chen and Mingqing Huang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Food Chemistry and Pharmacology & Therapeutics.

In The Last Decade

Mu‐Yang Huang

19 papers receiving 678 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mu‐Yang Huang Macao 14 303 239 229 109 65 20 690
Chunyu Wu China 15 284 0.9× 78 0.3× 148 0.6× 68 0.6× 68 1.0× 42 578
Xuan‐Run Wang Macao 9 284 0.9× 85 0.4× 99 0.4× 94 0.9× 41 0.6× 12 551
Yan‐Wei Xiang China 13 201 0.7× 133 0.6× 143 0.6× 51 0.5× 47 0.7× 26 577
Shreya Kar Singapore 6 290 1.0× 98 0.4× 138 0.6× 42 0.4× 37 0.6× 8 500
Ming Yue Li China 17 480 1.6× 127 0.5× 194 0.8× 59 0.5× 91 1.4× 30 884
Anqi Zeng China 17 435 1.4× 85 0.4× 131 0.6× 54 0.5× 50 0.8× 45 858
Qingxuan Zeng China 14 283 0.9× 136 0.6× 154 0.7× 43 0.4× 105 1.6× 21 673
Guoguo Jin China 14 350 1.2× 74 0.3× 142 0.6× 49 0.4× 31 0.5× 25 643
Ali H. El‐Bahrawy Egypt 10 179 0.6× 85 0.4× 122 0.5× 47 0.4× 45 0.7× 18 466
Chunpu Zou China 12 258 0.9× 80 0.3× 86 0.4× 44 0.4× 33 0.5× 24 458

Countries citing papers authored by Mu‐Yang Huang

Since Specialization
Citations

This map shows the geographic impact of Mu‐Yang Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mu‐Yang Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mu‐Yang Huang more than expected).

Fields of papers citing papers by Mu‐Yang Huang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mu‐Yang Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mu‐Yang Huang. The network helps show where Mu‐Yang Huang may publish in the future.

Co-authorship network of co-authors of Mu‐Yang Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Mu‐Yang Huang. A scholar is included among the top collaborators of Mu‐Yang Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mu‐Yang Huang. Mu‐Yang Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ye, Zihan, Wei‐Bang Yu, Mu‐Yang Huang, et al.. (2025). Repurposing Cardiac Glycosides to Potentiate CD47 Blockade through Calreticulin‐mediated Phagocytic Effects for Lung Cancer Treatment. Advanced Science. 12(46). e08245–e08245.
2.
Lyu, Wen-Yu, Jun Cao, Mu‐Yang Huang, et al.. (2025). Xerophenone H, a naturally-derived proteasome inhibitor, triggers apoptosis and paraptosis in lung cancer. Phytomedicine. 141. 156647–156647. 1 indexed citations
3.
Zhang, Lele, et al.. (2024). Immunogenic cell death inducers for cancer therapy: An emerging focus on natural products. Phytomedicine. 132. 155828–155828. 10 indexed citations
4.
He, Xinyu, Wen-Yu Lyu, Mu‐Yang Huang, et al.. (2023). Identification of Bulbocodin D and C as novel STAT3 inhibitors and their anticancer activities in lung cancer cells. Chinese Journal of Natural Medicines. 21(11). 842–851. 4 indexed citations
5.
Huang, Mu‐Yang, Mu‐Yang Huang, Yu‐Chi Chen, et al.. (2023). Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10. Pharmacological Research. 198. 106988–106988. 37 indexed citations
6.
Chen, Yu‐Chi, Qi Lu, Shi Wei, et al.. (2022). Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells. Biochemical Pharmacology. 197. 114940–114940. 34 indexed citations
7.
Yu, Wei‐Bang, et al.. (2022). Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives. Acta Pharmaceutica Sinica B. 13(4). 1467–1487. 28 indexed citations
8.
Xu, Yulian, Xiaoming Jiang, Mu‐Yang Huang, et al.. (2022). Glutathione peroxidase 8 expression on cancer cells and cancer‐associated fibroblasts facilitates lung cancer metastasis. SHILAP Revista de lepidopterología. 3(3). e152–e152. 8 indexed citations
9.
Zhao, Hong, Jin‐Jian Lu, Shi Wei, et al.. (2022). Identification of AHSA1 as a Potential Therapeutic Target for BreastCancer: Bioinformatics Analysis and in vitro Studies. Current Cancer Drug Targets. 22(2). 142–152. 3 indexed citations
10.
Xu, Yulian, Xiaoming Jiang, Mu‐Yang Huang, et al.. (2021). c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2. Acta Pharmaceutica Sinica B. 12(3). 1240–1253. 17 indexed citations
11.
Jiang, Xiaoming, Mu‐Yang Huang, Yulian Xu, et al.. (2021). Regulation of CD47 expression by interferon-gamma in cancer cells. Translational Oncology. 14(9). 101162–101162. 27 indexed citations
12.
Huang, Mu‐Yang, Xiaoming Jiang, Binglin Wang, Yang Sun, & Jin‐Jian Lu. (2020). Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacology & Therapeutics. 219. 107694–107694. 98 indexed citations
13.
Huang, Mu‐Yang, et al.. (2020). Regulation of CD47 expression in cancer cells. Translational Oncology. 13(12). 100862–100862. 74 indexed citations
14.
Jiang, Xiaoming, Yulian Xu, Mu‐Yang Huang, et al.. (2020). Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells. Phytomedicine. 80. 153394–153394. 42 indexed citations
15.
Zhang, Lele, Mu‐Yang Huang, Yong Yang, et al.. (2020). Bioactive platycodins from Platycodonis Radix: Phytochemistry, pharmacological activities, toxicology and pharmacokinetics. Food Chemistry. 327. 127029–127029. 75 indexed citations
16.
Chen, Yu‐Chi, Mu‐Yang Huang, Lele Zhang, et al.. (2020). Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells. Chinese Journal of Natural Medicines. 18(7). 517–525. 14 indexed citations
17.
Huang, Mu‐Yang, Xiaoming Jiang, Yulian Xu, et al.. (2019). Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells. Food and Chemical Toxicology. 131. 110537–110537. 54 indexed citations
18.
Zhang, Lele, Xiaoming Jiang, Mu‐Yang Huang, et al.. (2018). Nagilactone E suppresses TGF-β1-induced epithelial–mesenchymal transition, migration and invasion in non-small cell lung cancer cells. Phytomedicine. 52. 32–39. 18 indexed citations
19.
Huang, Mu‐Yang, Lele Zhang, Jian Ding, & Jin‐Jian Lu. (2018). Anticancer drug discovery from Chinese medicinal herbs. Chinese Medicine. 13(1). 35–35. 80 indexed citations
20.
Jiang, Xiaoming, Yulian Xu, Mu‐Yang Huang, et al.. (2017). Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. Acta Pharmacologica Sinica. 38(11). 1512–1520. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chunyu Wu Breakdown of academic impact, for papers by Xuan‐Run Wang Breakdown of academic impact, for papers by Yan‐Wei Xiang Breakdown of academic impact, for papers by Shreya Kar Breakdown of academic impact, for papers by Ming Yue Li Breakdown of academic impact, for papers by Anqi Zeng Breakdown of academic impact, for papers by Qingxuan Zeng Breakdown of academic impact, for papers by Guoguo Jin Breakdown of academic impact, for papers by Ali H. El‐Bahrawy Breakdown of academic impact, for papers by Chunpu Zou
Rankless by CCL
2026